{"id":35656,"date":"2024-04-26T01:08:41","date_gmt":"2024-04-26T01:08:41","guid":{"rendered":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/04\/26\/uk-patients-test-gamechanger-bespoke-mrna-jab-for-melanoma\/"},"modified":"2024-04-26T01:08:41","modified_gmt":"2024-04-26T01:08:41","slug":"uk-patients-test-gamechanger-bespoke-mrna-jab-for-melanoma","status":"publish","type":"post","link":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/04\/26\/uk-patients-test-gamechanger-bespoke-mrna-jab-for-melanoma\/","title":{"rendered":"UK patients test &#8216;gamechanger&#8217; bespoke mRNA jab for melanoma"},"content":{"rendered":"<div style=\"text-align:center\"><img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/i2.wp.com\/e3.365dm.com\/24\/04\/768x432\/skynews-cancer-melanoma_6533592.jpg?20240426000512&amp;resize=768,432&amp;ssl=1\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"UK patients test &#8216;gamechanger&#8217; bespoke mRNA jab for melanoma\" title=\"UK patients test &#8216;gamechanger&#8217; bespoke mRNA jab for melanoma\" \/><\/div><p> <br \/>\n<\/p>\n<div data-component-name=\"sdc-article-body\" data-highlight-intro=\"true\">\n<p>The world&#8217;s first personalised mRNA cancer jab for melanoma is being tested in British patients.<\/p>\n<p>The &#8220;gamechanger&#8221; jab also has the potential to stop bladder, lung and kidney <strong><a href=\"https:\/\/news.sky.com\/topic\/cancer-8503\" target=\"_blank\" rel=\"noopener\">cancer<\/a><\/strong>.<\/p>\n<p>It&#8217;s custom built for each person and tells the body to identify cancer cells and stops the disease returning.<\/p>\n<p>A stage-two trial found it significantly reduced the risk of cancer coming back in melanoma patients and now a final trial has been launched.<\/p>\n<p>University College London Hospitals NHS Foundation Trust (UCLH) is leading the phase.<\/p>\n<p>Dr Heather Shaw, co-ordinating investigator of the trial, said it was &#8220;one of the most exciting things we&#8217;ve seen in a really long time&#8221;.<\/p>\n<p>&#8220;This is a really finely honed tool,&#8221; she said.<\/p>\n<p>&#8220;To be able to sit there and say to your patients that you&#8217;re offering them something that&#8217;s effectively like the Fat Duck at Bray versus McDonald&#8217;s &#8211; it&#8217;s that level of cordon bleu that&#8217;s coming to them.<\/p>\n<p>&#8220;These things are hugely technical and finely generated for the patient. The patients are really excited about them.&#8221;<\/p>\n<p>The jab is an individualised neoantigen therapy (INT) and can trigger the immune system to fight the patient&#8217;s specific type of cancer.<\/p>\n<p>To create the personalised therapy, a tumour sample is removed and has its DNA sequenced &#8211; with artificial intelligence also playing a role.<\/p>\n<div class=\"sdc-article-widget sdc-article-image\">\n<figure class=\"sdc-article-image__figure\">\n<div class=\"sdc-article-image__wrapper\" data-aspect-ratio=\"16\/9\"><\/div><figcaption class=\"ui-media-caption\">\n        <span class=\"u-hide-visually\">Image:<\/span><br \/>\n        <span class=\"ui-media-caption__caption-text\">Dr Heather Shaw with Steve Young, one of those involved in the trial<br \/>\n        <\/span><br \/>\n      <\/figcaption><\/figure>\n<\/div>\n<p>Dr Shaw said: &#8220;This is very much an individualised therapy and it&#8217;s far cleverer in some senses than a vaccine.<\/p>\n<p>&#8220;It is absolutely custom built for the patient &#8211; you couldn&#8217;t give this to the next patient in the line because you wouldn&#8217;t expect it to work.&#8221;<\/p>\n<p>She added: &#8220;I think there is a real hope that these will be the gamechangers in immunotherapy.&#8221;<\/p>\n<p>The aim is to ultimately cure the cancer and eradicate any rogue cells that might not show on scans.<\/p>\n<p>The phase-two trial found people with high-risk melanomas who got the jab &#8211; alongside immunotherapy drug Keytruda &#8211; were about half (49%) as likely to die or have their cancer come back after three years than those who just had Keytruda.<\/p>\n<p>     <a href=\"https:\/\/news.sky.com\/download-app\" target=\"blank\" data-tracking-label=\"ui-app-promo-download-link\" class=\"ui-app-promo sdc-article-widget\" data-type=\"\" data-component-name=\"ui-app-promo\" rel=\"noopener\"><\/p>\n<p>    <\/a><\/p>\n<div class=\"sdc-article-widget sdc-article-strapline sdc-article-strapline--default-layout\" data-component-name=\"sdc-article-strapline\">\n<div class=\"sdc-article-strapline__link\">\n<div class=\"sdc-article-strapline__image-wrap\">\n                <picture><source srcset=\"https:\/\/e3.365dm.com\/24\/03\/320x180\/skynews-gfxwhatsapppromo-gfxwhatsapp_6490206.png 320w, https:\/\/e3.365dm.com\/24\/03\/640x380\/skynews-gfxwhatsapppromo-gfxwhatsapp_6490206.png 640w\" media=\"(max-width: 480px)\"><source srcset=\"https:\/\/e3.365dm.com\/24\/03\/256x256\/skynews-gfxwhatsapppromo-gfxwhatsapp_6490206.png 256w, https:\/\/e3.365dm.com\/24\/03\/512x512\/skynews-gfxwhatsapppromo-gfxwhatsapp_6490206.png 512w\" media=\"(min-width: 481px)\"><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/e3.365dm.com\/24\/03\/512x512\/skynews-gfxwhatsapppromo-gfxwhatsapp_6490206.png\" alt=\"Follow Sky News on WhatsApp\" class=\"sdc-article-strapline__image\"\/><br \/>\n                <\/source><\/source><\/picture>\n            <\/div>\n<div class=\"sdc-article-strapline__body\">\n                <span class=\"sdc-article-strapline__title\">Follow Sky News on WhatsApp<\/span><\/p>\n<p class=\"sdc-article-strapline__text\">Keep up with all the latest news from the UK and around the world by following Sky News<\/p>\n<p>                <a href=\"https:\/\/whatsapp.com\/channel\/0029Va868Fv8vd1UsF99tP1u\" class=\"sdc-article-strapline__button\" target=\"_blank\" rel=\"noopener\">Tap here<\/a>\n        <\/div>\n<\/p><\/div>\n<\/p><\/div>\n<p><strong>Read more from Sky News:<br \/><a href=\"https:\/\/news.sky.com\/story\/take-at-home-brain-cancer-treatment-for-children-will-soon-be-available-on-nhs-13121594\" target=\"_blank\" rel=\"noopener\">Take-at-home brain cancer treatment for kids soon available on NHS<\/a><\/strong><\/p>\n<p>The phase-three global trial will include a wider range of patients and researchers are hoping to recruit around 1,100 people.<\/p>\n<p>At least 60 to 70 patients across eight UK centres are set to be recruited and the twin therapy combination will also be tested in lung, bladder and kidney cancer.<\/p>\n<p>Professor Lawrence Young, from the University of Warwick, called it &#8220;one of the most exciting developments in modern cancer therapy&#8221;.<\/p>\n<p>&#8220;Interest in cancer vaccines has been reignited in recent years by a deeper understanding of how the body controls immune responses and by the advent of mRNA vaccines which makes developing a vaccine based on the immune profile of a patient&#8217;s own tumour much more straightforward,&#8221; said Prof Young.<\/p>\n<p>&#8220;The hope is that this approach could be extended to other cancers such as those of the lung and colon.&#8221;<\/p>\n<\/p><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/news.sky.com\/story\/uk-patients-test-gamechanger-bespoke-mrna-jab-for-melanoma-13123074\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The world&#8217;s first personalised mRNA cancer jab for melanoma is being tested in British patients. The &#8220;gamechanger&#8221; jab also has the potential to stop bladder, lung and kidney cancer. It&#8217;s custom built for each person and tells the body to identify cancer cells and stops the disease returning. A stage-two trial found it significantly reduced [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":35657,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","fifu_image_url":"https:\/\/e3.365dm.com\/24\/04\/768x432\/skynews-cancer-melanoma_6533592.jpg?20240426000512","fifu_image_alt":"","footnotes":""},"categories":[607],"tags":[24133,24996,10869,38832,27737,9164,848],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/35656"}],"collection":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/comments?post=35656"}],"version-history":[{"count":1,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/35656\/revisions"}],"predecessor-version":[{"id":35658,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/35656\/revisions\/35658"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media\/35657"}],"wp:attachment":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media?parent=35656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/categories?post=35656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/tags?post=35656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}